Evidence map›Paper›PMID 27130868›Full record

Trial reportAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2016

Long-Term Outcomes in Belatacept- Versus Cyclosporine-Treated Recipients of Extended Criteria Donor Kidneys: Final Results From BENEFIT-EXT, a Phase III Randomized Study.

A Durrbach, J M Pestana, S Florman, M Del Carmen Rial, L Rostaing, D Kuypers, A Matas, T Wekerle, M Polinsky, H U Meier-Kriesche and 2 more

Registry-linked trialOpen access · hybridAbstract readClinical Trial, Phase IIIComparative StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05316038 (Study of the Impact of Belatacept Conversion on Metabolic and Infectious Complications in Kidney Transplant Recipients at Grenoble-Alpes University Hospital), which is not on this map. Cited by 73 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
73citing papers in PubMed, 2 pooled it
12.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05316038 unknown statusnot on this mapstarted 2022, after this paper: background citation

Study of the Impact of Belatacept Conversion on Metabolic and Infectious Complications in Kidney Transplant Recipients at Grenoble-Alpes University Hospital

TypeobservationalSponsorUniversity Hospital, GrenobleRan2022 to 2024Enrolled100ConditionsKidney Transplant Infection, Cardiovascular Diseases, Immunosuppression, Kidney TransplantArmsOral glucose tolerance test
3 · Its place in the literature

Who cites it

73 citing papers in PubMed, 2 syntheses or guidelines pooled it, 152 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Immunosuppression in Older Kidney Transplant Recipients: A Randomized Controlled Trial.Journal of the American Society of Nephrology : JASN · 2026
    Trial
  4. Trial
  5. Posttransplant reduction in preexisting donor-specific antibody levels after belatacept- versus cyclosporine-based immunosuppression: Post hoc analyses of BENEFIT and BENEFIT-EXT.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2018
    Trial
  6. De novo donor-specific antibodies in belatacept-treated vs cyclosporine-treated kidney-transplant recipients: Post hoc analyses of the randomized phase III BENEFIT and BENEFIT-EXT studies.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2018
    Trial
  7. Ten-year outcomes in a randomized phase II study of kidney transplant recipients administered belatacept 4-weekly or 8-weekly.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2017
    Trial
  8. Efficacy and Safety Outcomes of Extended Criteria Donor Kidneys by Subtype: Subgroup Analysis of BENEFIT-EXT at 7 Years After Transplant.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2017
    Trial
  9. Long-Term Outcomes in Belatacept- Versus Cyclosporine-Treated Recipients of Extended Criteria Donor Kidneys: Final Results From BENEFIT-EXT, a Phase III Randomized Study.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2016
    Trial
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Real-world evidence regarding cancer, mortality, and graft failure risk with de novo belatacept use among kidney transplant recipients in the United States.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2025
    Article
  20. Article

13 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 8 institutions in 6 countries.

A DurrbachUniversity Hôpital of Bicêtre, Le Kremlin-Bicêtre, France. antoine.durrbach@bct.aphp.fr.
J M PestanaHospital do Rim, Sao Paulo, Brazil.
S FlormanMount Sinai Medical Center, New York, NY.
M Del Carmen RialInstituto de Nefrología, Buenos Aires, Argentina.
L RostaingUniversity Hospital, Toulouse, France.
D KuypersUniversity Hospitals Leuven, Leuven, Belgium.
A MatasUniversity of Minnesota, Minneapolis, MN.
T WekerleMedical University of Vienna, Vienna, Austria.
M PolinskyBristol-Myers Squibb, Lawrenceville, NJ.
H U Meier-KriescheBristol-Myers Squibb, Lawrenceville, NJ.
S MunierBristol-Myers Squibb, Braine-l'Alleud, Belgium.
J M GrinyóUniversity Hospital Bellvitge, Barcelona, Spain.
Bristol-Myers Squibb (United States) · USBellvitge University Hospital · ESBristol-Myers Squibb (Belgium) · BEHospital do Rim e Hipertensão · BRMedical University of Vienna · ATMount Sinai Medical Center · USUniversité Paris-Saclay · FRUniversity of Minnesota · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the Belatacept Evaluation of Nephroprotection and Efficacy as First-Line Immunosuppression Trial-Extended Criteria Donors (BENEFIT-EXT), extended criteria donor kidney recipients were randomized to receive belatacept-based (more intense [MI] or less intense [LI]) or cyclosporine-based immunosuppression. In prior analyses, belatacept was associated with significantly better renal function compared with cyclosporine. In this prospective analysis of the intent-to-treat population, efficacy and safety were compared across regimens at 7 years after transplant. Overall, 128 of 184 belatacept MI-treated, 138 of 175 belatacept LI-treated and 108 of 184 cyclosporine-treated patients contributed data to these analyses. Hazard ratios (HRs) comparing time to death or graft loss were 0.915 (95% confidence interval [CI] 0.625-1.339; p = 0.65) for belatacept MI versus cyclosporine and 0.927 (95% CI 0.634-1.356; p = 0.70) for belatacept LI versus cyclosporine. Mean estimated GFR (eGFR) plus or minus standard error at 7 years was 53.9 ± 1.9, 54.2 ± 1.9, and 35.3 ± 2.0 mL/min per 1.73 m

Indexed as

Kidney TransplantationAbataceptCyclosporineFemaleFollow-Up StudiesGlomerular Filtration RateGraft RejectionGraft SurvivalHumansImmunosuppressive AgentsKidney Failure, ChronicKidney Function TestsMaleMiddle AgedPrognosisProspective StudiesAbataceptCyclosporineImmunosuppressive Agentsclinical research/practiceclinical trialdonors and donation: deceaseddonors and donation: donation after circulatory death (DCD)donors and donation: extended criteriafusion proteins and monoclonal antibodies: belataceptimmunosuppressantkidney transplantation/nephrology

Identifiers

PMID27130868
PMCPMC5516151
OpenAlexW2342564718

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.